Platelet rich plasma (PRP) is a blood plasma product that contains elevated level of platelets and growth factors (at least four to ten times) than normal blood concentration. PRP is also called as also called platelet enriched plasma and platelet gel. While mostly derived from patient’s own blood, platelet rich plasma is widely used in the treatment of diseases such as orthopedic diseases, neurological diseases, and other minor injuries that require outpatient surgeries. Rising incidence of diseases such as orthopedic diseases, sports injuries, cardiovascular diseases, obesity, and neurological diseases and introduction of various devices for PRP preparation are the key factors that are likely to drive market growth. In addition, growing awareness about PRP therapy and its advantages, and aging population more prone to injuries and surgeries are the other factors that boost market growth. However, high cost of the devices and therapy and threat of treatment failures are some of the factors restricting the market growth to some extent.
The autologous PRP segment dominated the PRP market in Europe in 2013. The dominance of this market segment was due to increasing demand for allogenic platelet rich plasma products. Thus, the allogenic segment is estimated to grow at the highest growth rate during the forecast period from 2014 to 2022. The growth of this market segment was majorly due to reduced wound healing time and high concentration of growth factors containing platelet rich plasma products. In case of a patient diagnosed with one of the blood disorders (leukemia, hemocytopenia, etc) with less number of platelets in the blood and without any significant clinical action, where allogenic PRP treatment would be recommended.
Orthopedic was the largest application segment in 2013, accounting for 38.3% share of the PRP market in Europe. Large number of orthopedic and sports injuries and rise in geriatric population are the major factors driving the growth of this application segment. PRP products are widely used in cosmetic surgeries to enhance the rate of injury healing, improve facial aesthetics, and facelift treatments. In addition, cost-effectiveness and multiple applications of PRP in cosmetic surgeries are the major factors accelerating the growth of this segment. Therefore, these factors collectively propel the growth of cosmetic surgery application segment and it is estimated to grow at a highest rate during the forecast period from 2014 to 2022.
Geographically, the Europe platelet rich plasma market has been segmented as U.K., Germany, Italy, France, Spain and Rest of Europe. In 2013, U.K. dominated the Europe PRP market primarily due to increasing prevalence of orthopedic and reconstructive procedures and growing number of bariatric surgeries. Thus, PRP therapy is gaining wider acceptability as it provides effective treatment and faster recovery. For instance, tennis elbow affects around 300,000 people in the U.K. every year, where PRP is the most preferred treatment option. Moreover, growing preference for PRP therapy for sports injuries would boost market growth in the U.K.
The Europe PRP market is highly fragmented with the presence of a large number of small and large multinational players. Companies such as Arthrex, Inc., Biomet, Inc., and EmCyte Corporation dominated the Europe PRP market in 2013. Other minor players present in the Europe PRP market include AdiStem Ltd., Glofinn Oy, Medira Ltd., and Regen Lab SA.
Platelet rich plasma (PRP) is a blood plasma product in which concentration of platelets is elevated four to eight times than normal blood platelet concentration. PRP is also called platelet rich gel, platelet enriched plasma and platelet enriched gel. PRP is an effective treatment to treat various diseases such as orthopedic diseases, sports injuries, neurological diseases and cardiothoracic diseases. In addition, PRP therapy has an extensive application in cosmetic industry. This report studies the current scenario as well as future market potential for PRP in Europe.
The market overview section of the report comprises qualitative analysis of the overall PRP market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, various analyses such as event impact analysis, regulatory scenario and value chain analysis has also been provided. Event impact analysis encompasses major events occurred in past decade and are expected to occur during the forecast period and are likely to affect the market dynamics positively or negatively. Value chain analysis includes the study of major steps involved in the PRP preparation and distribution. Regulatory scenario includes the study of different regulatory norms and procedures that regulate the approval and commercialization of PRP devices and products.
The Europe PRP market has been segmented on the basis of types, origins and applications. On the basis of types, the Europe PRP market is categorized as pure-PRP (P-PRP), leukocyte-rich PRP (L-PRP) and pure PRF/leukocyte-rich PRF (L-PRF). Moreover, on the basis of origin, the PRP market has been segmented into autologous, homologous and allogenic PRP. Furthermore, on the basis of application, the Europe PRP market has been classified as neurosurgery, cosmetic surgery, orthopedic surgery, general surgery and others (cardiothoracic surgery, urology, periodontal surgery and oral and maxillofacial surgery). The market for these types, origins and applications has been extensively analyzed on the basis of factors such as usage pattern, sales revenue, geographic presence and technological developments. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period 2012 to 2022, considering 2013 as the base year. The report also provides compounded annual growth rate (CAGR) for each segment for the forecast period 2014 to 2022.
Geographically, the Europe market has been classified into U.K., Germany, France, Italy, Spain, and others. The market size and forecast for each region has been provided for the period 2012 to 2022, in terms of origin, types and applications, along with the CAGR (%) for the forecast period 2014 to 2022.
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the Europe PRP market, in terms of percentage share in 2013 has been discussed. Moreover, the market share analysis of key players in Europe has also been provided in the report. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the Europe PRP market such as Arthrex, Inc., Biomet, Inc., DePuy Synthes, Inc., Harvest Technologies Corp., Regen Lab SA, and Stryker Corporation. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies, and recent developments.
Euorpe Platelet Rich Plasma (PRP) market is segmented as follows:
Europe Platelet Rich Plasma (PRP) Market, by Types
- Pure-Platelet Rich Plasma (P-PRP)
- Leukocyte-Platelet Rich Plasma (L-PRP)
- Leukocyte-Platelet Rich Fibrin (L-PRF)
Europe Platelet Rich Plasma (PRP) Market, by Origin
Europe Platelet Rich Plasma (PRP) Market, by Applications
- Orthopedic Surgery
- Cosmetic Surgery
- General Surgery
- Other Surgeries (Oral and Maxillofacial, Cardiothoracic, Periodontal and Urological)
Europe Platelet Rich Plasma (PRP) Market, by Geography
- Rest of Europe